This Company Is Working On Six Problems That Show Up After 45

Fat gain. Lost muscle. Stiffer tissue. Lower resilience. Heart damage. Inflammation. One private biotech reports a program area related to each.

We Found a Company Trying to Grow Replacement Organ Systems, Not Just One Organ

Aging rarely damages one organ in isolation. This company is attempting to grow kidneys, livers, hearts, and other organs inside one coordinated developmental system.

The Company Developing More Time for Organ Transplantation

A review of organ-preservation technology, its public evidence and the milestones that would matter next.

The Company Developing a New Approach to Muscle Regeneration

One engineered protein. Human testing underway. A company-estimated market exceeding $40 billion.

A New Antimicrobial Platform for Bacteria, Fungi and Enveloped Viruses

Why a synthetic immune-defense company entered EverLife’s Research Scout list, and the human evidence that must come next

The Companies Studying Thymus Restoration

The Companies Studying Thymus Restoration

What 55 Mitochondrial Companies Are Trying to Solve

A few things about your own cells that most people get wrong, what fixing them could mean for your health and lifespan, and how to spot the companies actually worth watching before they hit the headlines.

What Rapamycin Research Has Demonstrated in Humans

I screened 24 mTOR programs. None clears the full framework today. Three milestones could change the evidence.

The Companies Studying Epigenetic Reprogramming

Scientists may have found a way to make old cells behave more like young cells. A human trial has begun. Let's see what the framework says.

What We Learned From 27 Stem-Cell Longevity Companies

I put twenty-seven stem-cell longevity companies through my screen. Almost none were ready. Two advanced.

Hibernation Biology May Hold a Longevity Key. Only 3 Companies Made Our Screen.

A longevity frontier almost nobody is covering, scored gate by gate

A Frog Freezes Solid Every Winter. Here's Who's Racing To Do It To People, And Who's Winning.

A frog freezes solid every winter, its heart stopped and its body full of ice, and hops away every spring. Nature already solved the thing the freezing companies are chasing. What that tells us about the most misunderstood frontier in longevity.

The Second Set of Rockets

Five kidney companies now on my research tracker, in one organ that quietly helps set your lifespan, from a man who approaches health and investing as though living to 120 is possible

The #1 Killer Is Finally Being Attacked At Its Root. The Obvious Investment Angle May Be the Weakest.

A wave of new drugs is targeting causes of heart disease. But the most advanced of them sit inside the largest companies on earth, where a single success barely moves the stock, and one of the biggest risk factors still has no approved treatment at all. Here is how I'm mapping where the real opportunity is, and isn't.

You Did Everything Right. The Cancer Most Likely To Kill You Isn't Being Looked For.

The Science Crossed A Line This Spring. Almost No One Noticed.

Four Different Diseases. One Hidden Alarm. And $1.6B+ In Pharma Money Moving Before Most Investors Have Heard Its Name.

Heart disease, Alzheimer’s, type 2 diabetes, and gout may share part of the same inflammatory machinery. Big pharma has already moved into the field. One company has shown, in early human studies, that this inflammatory signal can be quieted.

Longevity Biotech Research Tracker, Scouts And Watchlist

Disclosure: Eric holds personal equity in Repair Biotechnologies and Yuva Biosciences; both are conflict-flagged. Independent, impersonal research only. Not investment or medical advice.

Full Disclosure And Terms Of Research

Originally published February 21, 2026. Updated May 17, 2026.I want to be clear about what this publication is and isn't.